THE ROLE OF THE SOLUBLE TNF-ALPHA RECEPTORS IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/vsp.v11i4.356
Abstract
The results of the study of etanercept (soluble tumor necrosis factor alpha receptors) efficacy and safety in treatment of 97 patients with early and late onset of juvenile idiopathic arthritis are demonstrated in this article. The observation period was 12 months. In 48 weeks of anti-TNF treatment the achievement of clinical remission, decrease and normalization of laboratory markers of disease activity, complete restoration of joints function and improvement of life quality was established in 100% of children with early onset and 71% of children with late onset of arthritis. The drug was withdrawn in 13 (14%) patients: in 5 (6%) due to inefficiency, in 3 (4%) — due to development of side effects.
About the Authors
T. M. Bzarova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Yekaterina Alekseyeva, Doctor of Medical Science, professor, head of rheumatologic department of the Scientific Center of Children’s Health of the Russian Academy of Medical Science, dean of pediatric department of the I.M. Sechenov First Moscow State Medical University
Russian Federation
Yekaterina Alekseyeva, Doctor of Medical Science, professor, head of rheumatologic department of the Scientific Center of Children’s Health of the Russian Academy of Medical Science, dean of pediatric department of the I.M. Sechenov First Moscow State Medical University
A. N. Fetisova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
N. A. Zurikova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
S. I. Valieva
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
R. V. Denisova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. G. Chistyakova
Scientific Centre of Children Health, RAMS, Moscow
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
N. I. Taibulatov
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
M. V. Ryazanov
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
A. V. Anikin
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. I. Zelikovich
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
G. V. Kurilenkov
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. L. Semikina
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
References
1. Cassidy J. T., Petty R. E., Laxer R. M., Lindsley C. B. Textbook of pediatric rheumatology. 6th edn. Philadelphia: Saunders Elsevier. 2010. 794 с.
2. Баранов А. А. Педиатрия. Клинические рекомендации. М.: ГЭОТАР-Медиа. 2009. С. 387–420.
3. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит. Этиология. Патогенез. Клиника. Алгоритмы диагностики и лечения. Рук-во для врачей, преподавателей, научных сотрудников / под общ. ред. акад. РАМН, проф. А. А. Баранова. М.: ВЕДИ. 2007. С. 325–339.
4. Алексеева Е. И., Шахбазян И. Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Серия: Аутоиммунные заболевания. М. 2002; 5: 127.
5. Szer I. S., Kimura Yu., Malleson P. N., Southwood T. R. Arthritis in children and Adolescents. Juvenile Idiopathic Arthritis. Oxford University Press. 2006. 456 р.
6. Horneff G., Augustin S. Medical treatment of juvenile idiopathic arthritis. Med. Monatsschr. Pharm. 2008; 31: 326–336.
7. Hashkes P. J., Laxer R. M. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294: 1671–1684.
8. El-Gabalawy H. S., Lipsky P. E. Why do we not have a cure for rheumatoid arthritis? Arthritis Res. 2004; 4 (2): 297–301.
9. Foster H. E., Marshall N., Myers A. et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum. 2003; 48: 767–775.
10. Strand V., Singh J. A. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from rando mized controlled trials. Am. J. Manag. Care. 2008; 14 (4): 234–254.
11. Насонов Е. Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Терапевтический архив. 2007; 5: 5–8.
12. Minden K., Niewerth M., Listing J. et al. Long-term outcome in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2392–2401.
13. Алексеева Е. И., Валиева С.И., Денисова Р. В. Перспективы применения растворимых рецепторов к ФНО-_ в терапии ювенильных артритов. Вопросы современной педиатрии. 2008; 7 (5): 51–57.
14. Horneff G., Schmeling H., Biedermann T. et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 2004; 63 (12): 1638–1644.
15. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2009; 68 (4): 519–525.
16. Giannini E. H., Ilowite N. T., Lovell D. J. et al. Long-term safety and effec tiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009; 60 (9): 2794–2804.
17. Prince F. H. M., Twilt M., ten Cate R. et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann. Rheum. Dis. Published online 15 Apr 2008 doi: 10.1136/ard.2007.087411.
18. Hayward K., Wallace C. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis. Res. Ther. 2009; 11: 216 (doi: 10.1186/ar2619).
19. Breda L., Del Torto M., De Sanctis S., Chiarelli F. Biologics in children’s autoimmune disorders: efficacy and safety. Eur. J. Pediatr. (doi: 10.1007/s00431-010-1238-z).
20. Pain C., McCann L. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics: Targets & Therapy. 2009; 3: 127–139.
21. Никишина И. П. Этанерцепт в лечении ювенильного артрита: от опыта клинических исследований до клинической практики. РМЖ. 2010; 18 (27): 2–7.
Review
For citations:
Bzarova T.M., Alexeeva E.I., Fetisova A.N., Zurikova N.A., Valieva S.I., Denisova R.V., Mitenko E.V., Sleptsova T.V., Isaeva K.B., Chistyakova E.G., Taibulatov N.I., Ryazanov M.V., Anikin A.V., Zelikovich E.I., Kurilenkov G.V., Semikina E.L. THE ROLE OF THE SOLUBLE TNF-ALPHA RECEPTORS IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS. Current Pediatrics. 2012;11(4):29-37. (In Russ.) https://doi.org/10.15690/vsp.v11i4.356
Views:
1011
Email this article 
